Protocols for Assessment of In vitro and In vivo Bioactivation Potential of Drug Candidates

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 447-476

  Zhang, Zhoupeng ^a   Gan, Jinping ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bioactivation related toxicity; Electrophilic intermediates; Ion trap mass spectrometer

Indexed keywords

EID: 84889328902     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch14     Document Type: Chapter

References (65)

1. Afzal M, Afzal A, Jones A, Armstrong D. A rapid method for the quantification of GSH and GSSG in biological samples. In:Armstrong D, editor. Oxidative Stress Biomarkers and Antioxidant Protocols. Totowa, NJ: Human Press Inc; 2002. p 117-122.
2. Alt C, Eyer P. Ring addition of the a-amino group of glutathione increases the reactivity of benzoquinone thioethers. Chem Res Toxicol 1998;11:1223-1233.
3. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Meth Enzymol 1985;113:548-555.
4. Aust SD, Chignell CF, Bray TM, Kalyanaraman B, Mason RP. Free radicals in toxicology. Toxicol Appl Pharmacol 1993;120:168-178.
5. Bateman KP, Baker J, Wilke M, Lee J, LeRiche T, Seto C, Day S, Chauret N, Oqullet M, Nicoll-Griffith DA. Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol 2004;17:1356-1361.
6. Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem Res Toxicol 2002;15:1561-1571.
7. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995;25:207-235.
8. Boelsterli UA. Xenobiotic acyl glucuronide and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 2002;3:439-450.
9. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicity. Chem Res Toxicol 2000;13:135-160.
10. Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T. Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 2002;30:404-413.
11. Butterfield DA. b-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 1997;10:495-506.
12. Castro-Oerez J, Plumb R, Liang L, Yang E. A high-throughput liquid chromatography/ tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun Mass Spectrom 2005;19:798-804.
13. Cohen SD, Pumford NR, Khairallah EA, Boekelheide K, Pohl LR, Amouzadeh HR, Hinson JA. Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol 1997;143:1-12.
14. Coles B. Effects of modifying structure on electrophilic reactions with biological nucleophiles. Drug Metab Rev 1984-1985;15:1307-1334.
15. Comporti M. Three models of free radical-induced cell injury. Chem Biol Interact 1989;72:1-56.
16. Correia MA, Ortiz de Montellano, PR. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry third. New York: Kluwer Academic/Plenum Publishers; 2005; p 247-322.
17. Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG. A semiautomated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods 2005;52:278-285.
18. Degli Esposti M. Measuring mitochondrial reactive oxygen species. Methods 2002;26:335-340.
19. Dieckhaus CM, Fernandez-Metzler CL, King R, Krolikowski PH, Baillie TA. Negative ion tandom mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 2005;18:630-638.
20. Doss GA, Miller RR, Zhang Z, Teffera Y, Nargund RP, Palucki B, Park MK, Tang YS, Evans DC, Baillie TA, Stearns RA. Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazole. Chem Res Toxicol 2005;18:271-276.
21. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16.
22. Gan J, Hsueh MM, Qu Q, Harper TW, Humphreys WG. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol 2005;18:896-903.
23. Ge XS, Shen J, Subramanyam B, Tseng JL, editors. The development of a strategy for unambiguous identification of reactive intermediate/metabolite. 54th ASMS Conference on Mass Spectrometry and Allied Topics; 2006 May 28-June 1; Seattle. Washington: Poster # ThP 166;2006.
24. Gorrod JW, Sai Y. Recognition of novel artifacts produced during the microsomal incubation of secondary alicyclic amines in the presence of cyanide. Xenobiotica 1997;27:389-399.
25. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
26. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001;14:611-650.
27. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004;142:231-255.
28. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91(3A):7A-11A.
29. Ho B, Castagnoli N. Trapping of metabolically generated electrophilic species with cyanide ion: metabolism of 1-benzylpyrrolidine. J Med Chem 1980;23:133-139.
30. Iskander K, Jaiswal AK. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact 2005;153-154:147-157.
31. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-1506.
32. Kalgutkar AS, Dalvie DK, OoDonnell JP, Taylor TJ, Sahakian C. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr Drug Metab 2002;3:379-424.
33. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225.
34. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Ann Rev Pharmacol Toxicol 2004;44:239-267.
35. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF. Electrospray ionization mass spectrometric analysis of intact cytochrome P450:identification of tienilic acid adducts to P450 2C9. Biochemistry 1999;38:2312-2319.
36. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-420.
37. Loughlin AF, Skiles GL, Alberts DW, Schaefer WH. An ion exchange liquid chromatography/mass spectrometry method for the determination of reduced and oxidized glutathione and glutathione conjugates in hepatocytes. J Pharm Biomed Anal 2001;26:131-142.
38. Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, De Nardi C, Watt A. A quantitative high-throughput trapping assay as a measurement of potentialfor bioactivation. Anal Biochem 2006;351:266-272.
39. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer 1981;47(5 S): 1055-1064.
40. Muller L, Kikuchi Y, Probst G, Schechtman, L, Shimada, H, Sofuni, T, Tweats, D. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat Res 1999;436:195-225.
41. O'Brien PJ. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 1991;80:1-41.
42. Olsen J, Li C, Bjornsdottir I, Sidenius U, Hansen SH, Benet LZ. In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chem Res Toxicol 2005;18:1729-1736.
43. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005;45:177-202.
44. Parkinson A. Biotransformation of xenobiotics. In: Klaassen, CD, editor. Casarett & Doull's Toxicology: The Basic Sciences of Poisons. New York: McGraw-Hill Companies; 2001. p 133-224.
45. Pereg D, Robertson LW, Gupta RC. DNA adduction by polychlorinated biphenyls: adducts derived from hepatic microsomal activation and from synthetic metabolites. Chem Biol Interact 2002;139:129-144.
46. Ritter JK. Role of glucuronidation and UDP-glucuronosyltransferase in xenobiotic bioactivation reactions. Chem Biol Interact 2000;129:171-193.
47. Sallustio BC, Harkin LA, Mann MC, Krivickas SJ, Burcham PC. Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicol Appl Pharmacol 1997;147:459-464.
48. Sallustio BC, DeGraaf YC, Weekley JS, Burcham PC. Bioactivation of carboxylic acid compounds by UGT-glucuronosyltransferase to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. Chem Res Toxicol 2006;19:683-691.
49. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implication. Therap Drug Metab 2003; 25:1-6.
50. Smith MT, Evans CG, Thor H, Orrenius S. Quinone-induced oxidative injury to cells and tissues. In: Sies H, editor. Oxidative Stress. Orlando, FL: Academic Press Inc; 1985. p 91-113.
51. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization- tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 2004;36:105-116.
52. Svardal AM, Mansoor MA, Ueland PM. Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography. Anal Biochem 1990;184: 338-346.
53. Tang W, Miller RR. In vitro drug metabolism: thiol conjugation. In:Yan Z, Caldwell GW, editors. Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods. Totowa, NJ: Human Press Inc; 2005. p 369-383.
54. Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: the ''danger hypothesis'' and innate immune system. Chem Res Toxicol 1999;12:387-395.
55. Walgren JL, Mitchell MD, Thompson. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-361.
56. Wang J, Davis M, Li F, Azam F, Scatina J, Talaat R. A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem Res Toxicol. 2004;17:1206-1216.
57. Ward D, Kalir A, Trevor A, Adams J, Baillie T, Castagnoli N. Metabolic formation of iminium species: the metabolism of phencyclidine. J Med Chem 1982;25:491-492.
58. Welch KD, Wen B, Goodlett BR, Yi EC, Lee H, Reilly TP, Nelson SD, Pohl LR. Proteomic identification of potential susceptibility factors in drug-induced liver diseases. Chem Res Toxicol 2005;18:924-933.
59. Wen Z, Stern ST, Martin DE, Lee K-H, Smith PC. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(30,30-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab Dispos 2006;34:1436-1442.
60. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol 2004;14:473-486.
61. Yan Z, Caldwell GW. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal Chem 2004;76:6835-6847.
62. Yang XX, Hu ZP, Chan SY, Zhou SF. Monitoring drug-protein interaction. Clin Chim Acta 2006;365:9-29.
63. Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart JK, Klunk L, Mitroka J. Protein covalent binding of maxipost through a cytochrome P450- mediated orthoquinone methide intermediate in rats. Drug Metab Dispos 2003;31:837-845.
64. Zhang Z, Chen Q, Li Y, Doss GA, Dean BJ, Ngui JS, Elipe MS, Kim S, Wu JY, DiNinno F, Hammond ML, Stearns RA, Evans DC, Baillie TA, Tang W. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone-type metabolites. Chem Res Toxicol 2005;18:675-685.
65. Zhou S. Separation and detection methods for covalent drug-protein adducts. J Chromatogr B 2003;797:63-90.